Please Wait...

sRANKL (Total) // Total Soluble Receptor Activator of Nuclear Factor Kappa B Ligand

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Formerly known as TNF-related activation-induced cytokine (TRANCE), the receptor activator of Nf-κB ligand (RANKL) was initially identified as an osteoprotegerin ligand (Lacey et al., 2012). RANKL is a member of the TNF superfamily and exists as a transmembrane protein and in a soluble form (after proteolytic cleavage or alternative mRNA splicing). There are three known spliced variants in human and the smallest of these three variants lacks the transmembrane and the intracellular domain and is directly secreted. The two other variants can be shed and released by proteases (MMP-3, MMP-7, MMP-14, ADAM10, ADAM17 and ADAM19) (Schramek et al., 2010). RANKL, RANK, and osteoprotegerin are a key molecular regulation system for bone remodeling. RANKL is an essential factor for the maturation and survival of osteoclasts. With the Wnt/β-catenin, they are the two major signaling pathway in regulation of bone mass (Boyce and Xing, 2007).

Bioclinica Lab employs two assays to measure RANKL. The assays are designed for the measurement of free RANKL (using recombinant osteoprotegerin for capture and polyclonal antibodies for detection) and total RANKL (sandwich immunoassay) in human serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner